<DOC>
	<DOC>NCT00848081</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).</brief_summary>
	<brief_title>A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Stable on alpha blocker therapy for the treatment of BPH for at least 4 weeks prior to starting the study. Have not taken the following treatments within the indicated duration and agree not to use at any time during the study: 1. All other Benign Prostatic Hyperplasia therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication. 2. Overactive Bladder therapy (including antimuscarinics) for at least 4 weeks prior to receiving study medication. 3. Erectile Dysfunction therapy (including herbal preparations) for at least 4 weeks prior to receiving study medication. If taking finasteride or dutasteride, must have been taking treatment for at least 6 months. Currently receiving alphablocker therapy for the treatment of hypertension. History of symptoms associated with orthostasis, including recurrent episodes of dizziness, lightheadedness, loss of consciousness, or syncope. Treated with nitrates for any cardiac conditions. Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention). Have problems with kidneys, liver, or nervous system Have uncontrolled diabetes Have prostate cancer, are being treated for cancer or have clinical evidence of prostate cancer (PSA greater than 10 ng/ml at the start of study). Have had a stroke or a significant injury to brain or spinal cord.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Prostate</keyword>
	<keyword>BPH</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>BPH-LUTS</keyword>
	<keyword>LUTS</keyword>
	<keyword>Phosphodiesterase Inhibitors</keyword>
	<keyword>tadalafil</keyword>
	<keyword>alpha blockers</keyword>
</DOC>